{'fraction_non_alphanumeric': 0.02508361204013378, 'fraction_numerical': 0.0016722408026755853, 'mean_word_length': 5.655555555555556, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Neuroleptic malignant syndrome (NMS)].

Background Neuroleptic Malignant Syndrome (NMS) is a rare, acute and life threatening disorder of thermoregulation and neuromotor control. It is characterised by muscle rigidity, hyperthermia, altered consciousness and autonomic dysfunction through dopamine blockage following exposure to antipsychotic medication. It can range from mild with few signs and symptoms to an acute, severe syndrome that should be considered a medical emergency. NMS generally develops within the first 2 weeks of an antipsychotic drug being initiated or after a change of dose.